|Bid||3.2500 x 800|
|Ask||3.3700 x 3000|
|Day's Range||3.1202 - 3.3700|
|52 Week Range||1.6900 - 11.1700|
|Beta (3Y Monthly)||3.76|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The licensing deal for rigosertib in Greater China includes $6 million upfront in the form of $2 million cash, the purchase of $2 million in Onconova stock and the placement of $2 million in escrow for clinical development expenses.
The cancer therapy-focused company promoted from within when appointing a new CEO to take over the post previously held by a co-founder.
Onconova (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Newtown company swapped one share for every 15 shares held in a reverse split designed to boost the company's stock price and attract new investors.
In this analysis, my focus will be on developing a perspective on Onconova Therapeutics Inc’s (NASDAQ:ONTX) latest ownership structure, a less discussed, but important factor. When it comes to ownershipRead More...